Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.39 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.37 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293405 | 0.91 | CDK1 (0.44) | HSP90AB1HSP90AA1 | |
| SCHEMBL2911369 | 0.90 | PNP (0.35) | HDAC6HDAC1HDAC4HDAC2 | |
| SCHEMBL2912438 | 0.88 | HSP90AB1 (0.39) | HDAC1HDAC2HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL2912568 | 0.87 | PDE4A (0.35) | HSP90AB1HSP90AA1 | |
| SCHEMBL2996820 | 0.85 | POLB (0.37) | HDAC1HDAC2 | |
| SCHEMBL3288528 | 0.84 | HDAC1 (0.44) | HDAC6HDAC1HDAC2 | |
| SCHEMBL3291370 | 0.83 | HDAC6 (0.39) | HDAC6HSP90AB1HSP90AA1 | |
| SCHEMBL2909064 | 0.83 | CYP1A2 (0.38) | HDAC1HDAC2 | |
| SCHEMBL3134817 | 0.82 | HSP90AB1 (0.41) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL3293432 | 0.82 | FGFR1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358198-B1 | NOVEL ACYCLIC NUCLEOSIDE PHOSPHONATE DERIVATIVES, SALTS THEREOF AND PROCESS FOR THE PREPARATION OF THE SAME | LG LIFE SCIENCES LTD (KR) | 2010-08-25 | — | — | EP | claimed |
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | claimed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | claimed |
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | LG LIFE SCIENCES LTD. (KR) | 2006-03-09 | — | — | US | claimed |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2004-04-01 | — | — | US | claimed |
| US-7723319-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2010-05-25 | — | — | US | disclosed |
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | disclosed |
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | LG LIFE SCIENCES LTD. (KR) | 2006-03-09 | — | — | US | disclosed |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052346-A1 | Nucleoside phosphonate derivatives useful in the treatment of HIV infections | PNP, TYMP, ENTPD5 | HDAC6 2233/4885HDAC1 1485/4885HDAC4 1973/4885 |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | HDAC6 1806/4885HDAC1 2564/4885HDAC4 2399/4885 |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | HDAC6 1806/4885HDAC1 2564/4885HDAC4 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.